News
Archive: February 2025
Contract Wins in Alzheimer’s and Huntington’s Disease
27 February 2025 - London, UK. IXICO plc (AIM: IXI, “IXICO” or “the Company”) a global leader in neuroscience imaging, using its AI-driven platform to help advance therapy research in neurological disorders, today announces that it has signed a new commercial contract for a global Alzheimer’s Disease (AD) imaging analysis with a leading biotechnology company, and secured an additional project in Huntington’s Disease (HD) with an existing partner.
Huntington’s Disease consortium further validates IXICO’s AI imaging platform
12 February 2025 - London, UK. IXICO plc (AIM: IXI, “IXICO” or “the Company”) a global leader in neuroscience imaging, using its AI-driven platform to help advance drug development in neurological disorders, today announces, the generation of further evidence verifying the superiority of the ‘IXIQ.Ai’ analysis platform in the development and validation of imaging biomarkers for Huntington’s Disease (HD), in conjunction with the Huntington’s Disease Imaging Harmonisation (“HD-IH”) consortium.